Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
The purpose of this clinical study is to identify the maximum tolerated dose (MTD) of BMS-690514 once daily orally in Japanese subjects with advanced or metastatic solid tumors.
Cancer
DRUG: BMS-690514
To determine the Maximum Tolerated Dose, the Dose Limiting Toxicity of BMS-690514, administered orally every day 28 days
Evaluate safety, exposure levels of BMS-690514 in the body & anticancer activity of BMS-690514 administered orally every day for 28 days., throughout the study|Safety evaluations and laboratory assessments will be performed, throughout the study|Preliminary markers of efficacy will also be assessed, throughout the study
The purpose of this clinical study is to identify the maximum tolerated dose (MTD) of BMS-690514 once daily orally in Japanese subjects with advanced or metastatic solid tumors.